Click and hear Paul G. Richardson present the data for the combination therapy with elotuzumab in combination pomalidomide and dexamethasone for relapsed/refractory multiple myeloma. Elotuzumab, an immunostimulatory monoclonal antibody targeting SLAMF7, enables selective killing of MM cells through multiple mechanisms of action and synergizes with the immunomodulatory drug pomalidomide. This study demonstrated sustained and clinically relevant PFS and OS benefits for elotuzumab plus pomalidomide and dexamethasone vs pomalidomide in combination with dexamethasone, with no new safety signals. These data support the long-term favorable efficacy–safety profile of elotuzumab plus pomalidomide and dexamethasone and suggest this regimen could be considered as a standard of care for patients with relapsed/refractory multiple myeloma after failure of lenalidomide and a proteasome inhibitor.

Despite recent advances in MM therapy, the disease remains incurable. Patients with late-stage RRMM refractory to pomalidomide and/or daratumumab have limited effective treatment options. Melflufen is a novel peptide-conjugated alkylator potentiated by intracellular aminopeptidases, which are markedly overexpressed in multiple myeloma. In this MEDtalk Paul G. Richardson present updated efficacy and safety of melflufen + low-dose dexamethasone in patients refractory to pomalidomide and/or daratumumab (HORIZON-study).

The SAM domain and HD domain 1 (SAMHD1) protein is a deoxynucleoside triphosphate (dNTP) triphosphohydrolase, which has been initially described to restrict human immunodeficiency virus type 1 (HIV-1) in the immune cells.  This study shows that SAMHD1 is expressed in approximately half of de novo diffuse large B-cell Lymphomas at a variable level and correlates with cell of origin (GC), biomarkers of tumor aggressiveness (eg MYC, proliferation) and clinical outcome.     

MEST SETE MEDtalks

Chronic Lymphocytic Leukaemia - Upfront Treatment   Se hele webinar

Chronic Lymphocytic Leukaemia – Upfront Treatment

<script src="https://fast.wistia.com/embed/medias/x9hmg3bo4e.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_x9hmg3bo4e seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/x9hmg3bo4e/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
Chronic Lymphocytic Leukaemia - Upfront Treatment&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/chronic-lymphocytic-leukaemia-upfront-treatment/'>Se hele webinar
Chronic Lymphocytic Leukaemia - Upfront Treatment

ASH 2018: Individuel CLL-behandling er vigtigere end nogensinde

<script src="https://fast.wistia.com/embed/medias/86wpowlp65.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_86wpowlp65 seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/86wpowlp65/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASH 2018: Individuel CLL-behandling er vigtigere end nogensinde&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/ash-2018-individuel-cll-behandling-er-vigtigere-end-nogensinde/'>Se hele webinar
ASH 2018: Individuel CLL-behandling er vigtigere end nogensinde

ASH 2018: Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients – in Real-World Clinical Practice

<script src="https://fast.wistia.com/embed/medias/kbs3mjg440.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_kbs3mjg440 seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/kbs3mjg440/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASH 2018: Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients – in Real-World Clinical Practice&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/ash-2018-efficacy-and-safety-of-ponatinib-in-cml-and-ph-all-patients-in-real-world-clinical-practice/'>Se hele webinar
ASH 2018: Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients – in Real-World Clinical Practice

Nye behandlingsmuligheder for Waldenströms makroglobinnæmi

<script src="https://fast.wistia.com/embed/medias/hh14f2khik.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_hh14f2khik seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/hh14f2khik/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
Nye behandlingsmuligheder for Waldenströms makroglobinnæmi&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/nye-behandlingsmuligheder-for-waldenstroms-makroglobinnaemi/'>Se hele webinar
Nye behandlingsmuligheder for Waldenströms makroglobinnæmi

In this MEDtalk Stine Mikkelsen present the first study investigating submicroscopic copy number variations/ uniparental disomy in idiopathic cytopenia of undetermined significance patients. In a subset of patients with otherwise no detectable genetic abnormalities, Stine Mikkelsen and colleagues identified structural variations involving genes recurrently affected in MDS. Their results suggest that SNP-A can aid the prognostics of ICUS patients by identifying submicroscopic structural variations as risk markers for poor OS.   

TOURMALINE-MM3 is a phase 3, double-blind, placebo-controlled study, where ixazomib improved PFS, and is the first study to evaluate the impact of maintenance therapy on quality of life in postautologous stem cell transplant in newly diagnosed multiple myeloma. In this MEDtalk Fredrik Schjesvold present the data from the study showing, that active treatment with ixazomibdid not have an adverse impact on HRQoL. 

The Nordic Myeloma Study Group (NMSG) initiated the CARFI trial, an open randomized phase II study, to investigate the efficacy and safety of carfilzomib as part of induction and conditioning in salvage ASCT and to evaluate the role of carfilzomib/dexamethasone maintenance after salvage ASCT. In this MEDtalk Henrik Gregersen report that maintenance therapy with carfilzomib and dexamethasone maintenance prolongs median time to progression with approximately 6 months following salvage ASCT in multiple myeloma.   

#Seneste udgivelse

Hæmatologi

Nr. 25 • maj 2019
9. Årgang
  • Myelomatose
  • Waldenström’s Macroglobulinæmi
  • Akut lymfatisk leukæmi

EHA 2019

ASH 2018

#

Hæmatologi

Carsten Utoft Niemann

Carsten Utoft Niemann
overlæge, ph.d.

Peter Hokland

Peter Hokland
Overlæge, dr.med., lærestolsprofessor,
forskningsrådsprofessor

Anne Stidsholt Roug

Anne Stidsholt Roug
afdelingslæge, ph.d.,